Abeille Pharmaceuticals, Inc.
SymBio Pharmaceuticals Limited

ABEILLE LICENSES AB-1001 TO SYMBIO PHARMACEUTICALS FORCOMMERCIALIZATION IN JAPAN AND PACIFIC RIM COUNTRIES
Company To Initiate Phase III Trial in 2Q

Princeton, NJ, March 16, 2007 - Abeille Pharmaceuticals, Inc., and SymBio Pharmaceuticals
Limited today announced the signing of an exclusive License and Distribution Agreement todevelop and sell AB-1001, Abeille’s transdermal patch for emesis, in Japan, China (including
Hong Kong), Korea, Taiwan and Singapore. For the right to develop and sell AB-1001 in theaforementioned territories, SymBio will pay Abeille an upfront licensing fee, and payments basedon achievement of specific milestones, that could total up to $21 million. The Agreement also
calls for double-digit royalty payments on commercial sales. As part of the Agreement, Abeillehas also granted to SymBio the right of first refusal on Abeille’s next product in the Field.
AB-1001, is a transdermal patch for chemotherapy induced nausea and vomiting (CINV). AB1001 is designed to deliver a commercially available 5HT3-antagonist, through the skin for acontinuous period of up to five days, thereby providing the patient with sustained relief fromCINV. Abeille has successfully completed a Phase I pharmacokinetic study, and a Phase II
irritation and sensitization studies, under a US IND. In late 2006, the company reached agreement
through a Special Protocol Assessment (SPA) with the FDA on its intended Phase III study designand intends to initiate a multinational Phase III trial in 2Q 2007.
“We are extremely pleased with the signing of this License and Distribution Agreement withSymBio.” stated Suresh Borsadia, President and CEO of Abeille. “In SymBio, we have a partnerthat shares our vision of bringing QUALITY products to patients in need with SPEED to market.
Mr. Fuminori Yoshida, President and CEO of SymBio has assembled an experienced team ofsenior executives at SymBio that have a track record of developing and marketing oncology
related products in Japan and the region. This partnership leverages that experience to ensure thatthe product is developed to maximize commercial success”“We are impressed with Abeille’s expertise in product development of innovative drug delivery
systems and we are looking forward to our collaboration with them,” said Fuminori Yoshida,Representative Director, President and Chief Executive Officer of SymBio. “This collaboration
for the development of the transdermal patch for chemotherapy induced nausea and vomiting aswell as the next product will be complementary to our pipeline portfolio that is focused ontherapeutics in oncology and hematology. I am very excited to partner with Abeille to deliver
important supportive care products to cancer patients in Japan, China, Korea, Taiwan andSingapore.”

About Abeille Pharmaceuticals
Abeille Pharmaceuticals, Inc. is a privately-held pharmaceutical company based in Princeton,
New Jersey. The Company is focused on the formulation of products by applying advanced
delivery technologies to existing drugs. These advanced delivery technologies include oral
controlled release and transdermal delivery systems. The new products may benefit patients byrequiring a lower dose of medicine, reduced side effects and easier administration of medication,
thereby encouraging a patient to use the medication as prescribed. Abeille is dedicated to thedevelopment and commercialization of products that address unmet medical needs and improve
the quality of life for patients. The Company’s initial focus will be on drugs used to treat
oncology related discomforts (such as CINV), diabetes and metabolic disorders, and CNS.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals’ focus is on oncology/hematology and autoimmune disease therapies.
Established in march 2005 by Fuminori Yoshida, who previously served as both Corporate Vice
President of Amgen Inc. and president of Amgen Japan, SymBio Pharmaceuticals’ underlying
corporate philosophy is “delivering hope to patients in need,” and the company aims to address
unmet medical needs of patients in Japan by cultivating a mutually beneficial or symbiotic
relationship among physicians, scientists, regulatory agencies, and investors. SymBio
Pharmaceuticals core philosophy is that profitability and socially responsibility as apharmaceutical enterprise can go hand in hand, and need not be mutually exclusive.

-MoreFor more information contact:
Dr. Suresh Borsadia
President and CEO
Abeille Pharmaceuticals, Inc.
116 Village Boulevard
Suite 200
Princeton, NJ 08540.
USA
Phone: +1 609 951 2204
http://www.abeillepharma.com

Mr. Fuminori Yoshida
Representative Director
President and Chief Executive Officer
SymBio Pharmaceuticals Limited
San-Ei Building 8th Floor
5-23-7 Shimbashi, Minato-ku
Tokyo 105-004.
JAPAN
Phone: +813 5472 1125
E-mail: Please send your inquiry through“INQUIRY” in our homepage
http://www.symbiosis.co.jp/en